Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New TestInvestors Business Daily • 03/11/21
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use NodBenzinga • 03/11/21
GlaxoSmithKline recommended to stop COVID-19 treatment trials early because of high efficacyProactive Investors • 03/11/21
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19GlobeNewsWire • 03/11/21
GlaxoSmithKline plc (GSK) Presents at Barclays Global Healthcare Conference 2021 (Transcript)Seeking Alpha • 03/10/21
Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to FluThe Motley Fool • 03/05/21
Will Sanofi and GlaxoSmithKline Be Too Late to the Party With Their COVID Vaccine?The Motley Fool • 03/05/21
Vir Stock Craters On Weak Results For Glaxo-Partnered Covid TreatmentInvestors Business Daily • 03/03/21
GlaxoSmithKline plc (GSK) Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/02/21
GSK to refocus study of experimental COVID-19 antibody treatment on patients 70 and olderMarket Watch • 02/25/21
GlaxoSmithKline tweaks COVID-19 treatment study after missing primary goalProactive Investors • 02/25/21
GlaxoSmithKline and Sanofi to push ahead with phase II trial of Covid-19 vaccineProactive Investors • 02/22/21
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidateGlobeNewsWire • 02/22/21
Sandoz announces agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibioticsGlobeNewsWire • 02/11/21